While EGFR sensitising mutations such as L858R and exon 19 deletions are associated with benefit from EGFR TKIs in patients with NSCLC, acquired resistance at least to gefitinib and erlotinib occurs with the emergence of the T790M mutation. This evidence concerns the gene EGFR and non-small cell lung carcinoma.